Business Context and Reporting Period
This Form 8-K Current Report was filed by Emerald Bioscience, Inc. (Nevada) on December 17, 2019. The filing details material agreements, governance changes, and a proposed corporate name change to "EMBI Pharmaceuticals, Inc." pending regulatory and stockholder approval.
Key Financial Metrics and Agreements
- Debt Reduction: Emerald Health Sciences (EHS) exercised 40.80 million warrants, paying an aggregate exercise price of approximately $4.08 million. This amount was applied as a reduction of obligations under the Multi Draw Credit Agreement.
- Remaining Debt: Following the warrant exercise, the reduced outstanding balance under the Credit Agreement is $2,014,500.
- Historical Expenses: Under the terminated Independent Contractor Agreement with EHS, the Company incurred expenses of $150,000 for the three months ended September 30, 2019, and $450,000 for the nine months ended September 30, 2019.
- New Compensation: A new Independent Contractor Services Agreement with Dr. Avtar Dhillon establishes a monthly fee of $10,000 ($5,000 cash, $5,000 accruing until a material financing is completed).
Material Changes Versus Prior Period
- Agreement Termination: The Independent Contractor Agreement with EHS (dated February 1, 2018) was terminated, effective December 31, 2019.
- Leadership Transition: Dr. Avtar Dhillon resigned as Chairman of the Board and Chairman of the Finance and Business Development Committee. Punit Dhillon was appointed to fill these vacancies.
- Corporate Identity: The Board approved a name change from Emerald Bioscience, Inc. to EMBI Pharmaceuticals, Inc.
Outlook, Risks, and Management Commentary
- Board Observer Rights: EHS retains the right to designate a non-voting board observer (Dr. Avtar Dhillon) for as long as it holds securities in the Company.
- Contingent Payments: A portion of Dr. Dhillon's new advisory fee is contingent upon the Company completing a material financing.
- Regulatory Approval: The proposed name change is subject to regulatory and stockholder approval.
- Financial Data Limitations: This filing does not provide current revenue, profit, cash flow, or margin data for the reporting period.
Investor Verification Checklist
- Verify the final approval status of the name change to "EMBI Pharmaceuticals, Inc."
- Confirm the exact terms of the remaining $2,014,500 debt obligation under the Credit Agreement.
- Monitor the Company's progress toward a "material financing" to trigger the accrued portion of Dr. Dhillon's fees.
- Review the full text of the Warrant Exercise Agreement (Exhibit 10.1) for additional covenants or conditions.